CME/CNE Information



Activity Title Advances in Multiple Sclerosis (AIMS) Primer, 2nd Edition
Topic Multiple Sclerosis
Accreditation Type AMA PRA Category 1 Credits™/ANCC Contact Hours
Release Date December 2015
Expiration Date December 30, 2016
Estimated Time to Complete Activity 120 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Summarize new developments among platform therapies for MS, as well as recent, relevant data regarding their effectiveness and safety
  • Differentiate between key characteristics of newer (non-platform) MS therapies that should be considered when starting or switching treatment
  • Review recommendations and expert opinion regarding timely and effective monitoring of MS activity and progression
  • Evaluate criteria that can support the decision to initiate or switch treatment
  • Improve communication and coordination among multidisciplinary clinicians who manage patients with MS
  • Apply components of the comprehensive care model into the management of patients with MS
  • Identify the dimensions of wellness as it relates to MS


FACULTY

Daniel Ontaneda, MD, MSc
Neurologist
Mellen Center for MS Treatment & Research
Cleveland Clinic
Cleveland, Ohio

Marie Namey, APRN, MSCN
Clinical Nurse Specialist
Mellen Center for MS Treatment & Research
Cleveland Clinic
Cleveland, Ohio

Jacqueline A. Nicholas, MD, MPH
Neuroimmunologist
OhioHealth Multiple Sclerosis Center
Columbus, Ohio


METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CNE information.
  3. Complete the CME/CNE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CNE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  6. Credit documentation/reporting: your CME/CNE certificate will be available for download.


TECHNICAL REQUIREMENTS

This site is best viewed using Internet Explorer 10.0 or higher, Google Chrome 29.0 or higher, Firefox 30.0 or higher. For interactive content, a broadband connection is required. For all CME/CNE activities featuring audio you must have a sound card and speakers.

Our interactive activities may require the Adobe Flash Player (available from the Adobe Web site) and Adobe Shockwave Player (available from the Adobe Web site). Both browser plug-ins are free.

Our activities may require JavaScript to be enabled on your computer.


ACCREDITED PROVIDER

This activity is provided by Consortium of Multiple Sclerosis Centers and Nurse Practitioner Alternatives in collaboration with The France Foundation.


TARGET AUDIENCE

This activity is intended for neurologists, nurses, nurse practitioners, physician assistants, rehabilitation professionals, case managers, mental health professionals, social workers and others involved in the management of patients with MS.


STATEMENT OF NEED

The number of FDA-approved disease modifying therapies (DMTs) for patients with MS has grown considerably over the last 2 decades. These agents vary by mechanism of action, mode of administration, dosing frequency, side effect profiles and monitoring recommendations. The increasing range of treatment options allows for individualized treatment selection for this patient population and it is critical that clinicians managing patients with MS are familiar with current evidence to support optimal treatment decisions over the disease course. In addition, a multi-dimensional, comprehensive care approach is advocated to promote positive outcomes for individuals with MS. All members of the MS health care team need awareness of how to incorporate the principles of comprehensive care in clinical practice.


ACCREDITED PROVIDER

This activity is provided by the Consortium of Multiple Sclerosis Centers and Nurse Practitioner Alternatives in collaboration with The France Foundation.


ACCREDITATION STATEMENT

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


CREDIT DESIGNATION

Physicians
The Consortium of Multiple Sclerosis Centers designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is awarded 2.0 contact hour(s) of continuing nursing education for RNs and APRNs.

Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.


DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC, NPA, and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC, NPA, and TFF to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC, NPA, and TFF committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.


Activity Staff Disclosures

June Halper has disclosed that she serves as a Consultant for non-clinical subject matter to Biogen Idec. All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at the Consortium of Multiple Sclerosis Centers who control content have no relevant financial relationships to disclose.

The planners, reviewers, and staff at Nurse Practitioner Alternatives who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.


Faculty Disclosure


The following faculty report that they have relevant financial relationships to disclose:

  • Daniel Ontaneda, MD, MSc has received grants/research support from Genzyme, National Institutes of Health, NMSS, and Novartis. He has served as a consultant for Genzyme, Mallinckrodt, and Novartis.
  • Marie Namey, APRN, MSCN has served as a consultant for Biogen Idec, Genentech, Genzyme, Mallinckrodt, Novartis and Teva Neuroscience. She has received honorarium from Acorus Therapeutics, Biogen Idec, Genentech, Genzyme, Mallinckrodt, Novartis, and Teva Neuroscience.
  • Jacqueline A. Nicholas, MD, MPH has received grants/research support from Biogen Idec, Genzyme, Novartis, and Teva Pharmaceuticals. She has also served as a consultant for Biogen Idec, Genzyme, Medtronic, Novartis, Teva Pharmaceuticals and has received honoraria from Biogen Idec, Genzyme, Novartis, and Teva Pharmaceuticals.

Disclosure of Unlabeled Use

CMSC, NPA, and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC, NPA, and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by educational grants from Biogen and Mallinckrodt Pharmaceuticals.


DISCLAIMER

CMSC, NPA, and TFF present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC, NPA, and TFF assume no liability for the information herein.


COPYRIGHT INFORMATION

Copyright © 2015 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.


CONTACT INFORMATION

If you have questions about this CME/CNE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.